BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 25398989)

  • 1. Vasculopathy and pulmonary hypertension in sickle cell disease.
    Potoka KP; Gladwin MT
    Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L314-24. PubMed ID: 25398989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
    Nader E; Romana M; Connes P
    Front Immunol; 2020; 11():454. PubMed ID: 32231672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravascular hemolysis and the pathophysiology of sickle cell disease.
    Kato GJ; Steinberg MH; Gladwin MT
    J Clin Invest; 2017 Mar; 127(3):750-760. PubMed ID: 28248201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
    Kato GJ; Gladwin MT
    JAMA; 2008 Dec; 300(22):2638-46. PubMed ID: 19066384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.
    Hsu LL; Champion HC; Campbell-Lee SA; Bivalacqua TJ; Manci EA; Diwan BA; Schimel DM; Cochard AE; Wang X; Schechter AN; Noguchi CT; Gladwin MT
    Blood; 2007 Apr; 109(7):3088-98. PubMed ID: 17158223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sickle cell disease, vasculopathy, and therapeutics.
    Kassim AA; DeBaun MR
    Annu Rev Med; 2013; 64():451-66. PubMed ID: 23190149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sickle cell disease vasculopathy: a state of nitric oxide resistance.
    Wood KC; Hsu LL; Gladwin MT
    Free Radic Biol Med; 2008 Apr; 44(8):1506-28. PubMed ID: 18261470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sickle cell anemia and vascular dysfunction: the nitric oxide connection.
    Akinsheye I; Klings ES
    J Cell Physiol; 2010 Sep; 224(3):620-5. PubMed ID: 20578237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular pathophysiology of sickle cell disease.
    Connes P; Renoux C; Joly P; Nader E
    Presse Med; 2023 Dec; 52(4):104202. PubMed ID: 37944640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.
    Gordeuk VR; Castro OL; Machado RF
    Blood; 2016 Feb; 127(7):820-8. PubMed ID: 26758918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease.
    Gbotosho OT; Kapetanaki MG; Kato GJ
    Front Immunol; 2020; 11():561917. PubMed ID: 33584641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular complications of sickle cell disease.
    Usmani A; Machado RF
    Clin Hemorheol Microcirc; 2018; 68(2-3):205-221. PubMed ID: 29614633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
    Wood KC; Granger DN
    Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.
    Kato GJ; McGowan V; Machado RF; Little JA; Taylor J; Morris CR; Nichols JS; Wang X; Poljakovic M; Morris SM; Gladwin MT
    Blood; 2006 Mar; 107(6):2279-85. PubMed ID: 16291595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.
    Villagra J; Shiva S; Hunter LA; Machado RF; Gladwin MT; Kato GJ
    Blood; 2007 Sep; 110(6):2166-72. PubMed ID: 17536019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythrocyte and plasma oxidative stress appears to be compensated in patients with sickle cell disease during a period of relative health, despite the presence of known oxidative agents.
    Detterich JA; Liu H; Suriany S; Kato RM; Chalacheva P; Tedla B; Shah PM; Khoo MC; Wood JC; Coates TD; Milne GL; Oh JY; Patel RP; Forman HJ
    Free Radic Biol Med; 2019 Sep; 141():408-415. PubMed ID: 31279092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.
    Morris CR; Kato GJ; Poljakovic M; Wang X; Blackwelder WC; Sachdev V; Hazen SL; Vichinsky EP; Morris SM; Gladwin MT
    JAMA; 2005 Jul; 294(1):81-90. PubMed ID: 15998894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of Sickle Cell Disease.
    Sundd P; Gladwin MT; Novelli EM
    Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemolysis-associated pulmonary hypertension in thalassemia.
    Morris CR; Kuypers FA; Kato GJ; Lavrisha L; Larkin S; Singer T; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():481-5. PubMed ID: 16339702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular complications in patients with sickle cell disease.
    Gladwin MT
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):423-430. PubMed ID: 29222288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.